

# ***Echinacea* spp.: A Monograph & What's New**

Kevin Spelman, PhD

Note to the participant: The majority of the lecture will focus on the “What’s New” section below.

## **Botany**

Depending on how this Asteraceae family member is classified, there are up to 12 different species of *Echinacea*. The most commonly used species for medicinal purposes is *Echinacea purpurea*, which is easy to cultivate and therefore, product demand does not put a stress on native populations of *Echinacea* species that are difficult to cultivate. Most preparations found in the market are derived from the above ground, or aerial, parts of *E. purpurea* and/or underground parts of *E. purpurea*; these preparations account for 80% of commercial production.<sup>1</sup> In addition, *E. angustifolia* and *E. pallida* are also utilized in commerce but much less than *E. purpurea*.<sup>2</sup>

## **Chemistry**

All three species of *Echinacea* seen in commercial preparations have undergone chemical and pharmacological studies.<sup>3</sup> However, there are several other species of *Echinacea* that have little to no research on their chemistry and pharmacology. Due to the similarities between *Echinacea* species, the current body of scientific literature on *Echinacea* can be confusing due to the three species in use – namely *E. purpurea*, *E. pallida* and *E. angustifolia*. These three have phytochemical similarities but have notable differences, particularly around the identity and concentration of key constituents.<sup>4-6</sup> A number of German studies in the 1980s were called into question when it was discovered that the species they intended to study was the wrong *Echinacea* species.

Because of multiple species, plant parts, and preparations used, there are different constituent profiles for various products.<sup>7</sup> “*Echinacea*” may refer to the roots, aerial parts, whole plant or a combination of the above; *Echinacea* products can be made from fresh or dried plant parts, and may be prepared by juicing, alcohol extraction, infusion, decoction, or consumed as tablets or capsules.<sup>8</sup> Most preparations are derived from the aerial parts of *E. purpurea* and/or underground parts of *E. purpurea*, *E. angustifolia*, or *E. pallida*.

In spite of the prolific research done on *Echinacea* spp., there is still uncertainty as to which constituents *primarily* contribute to the immunomodulatory action of *Echinacea* species, although many believe it to be the alkylamides.<sup>9</sup> Importantly, despite the recent focus on the alkylamides, it appears that multiple constituent groups are responsible for *Echinacea*'s activity.<sup>10,11</sup> Since *E. purpurea* makes up most of the *Echinacea* material available this discussion will be limited to that species.

To date more than 216 different phytochemicals have been identified in the literature based on *E. purpurea*.<sup>9</sup> These compounds cover a diverse number of constituent families with varying polarities. Besides the alkylamides, three other constituent groups may have activity; the hydroxycinnamates (eg. caffeic acid derivatives), the polysaccharides and the glycoproteins.<sup>12,4</sup> More divergent research points at generally unrecognized, but active, lipopolysaccharides and/or lipoproteins present in *Echinacea* root

capsule and extracts occurring from the endophytes of the roots,<sup>13-15</sup> although this is not yet well established.

In regard to tincture extractions with ethanol concentrations above 40%, only very low levels of polysaccharides are left in suspension, and denaturing of proteins is expected.<sup>11,16</sup> Thus, the major constituents of ethanolic *Echinacea* extracts are caffeic acid derivatives and alkylamides (and possibly the before mentioned lipopolysaccharides and/or lipoproteins). The capsule or powder of *Echinacea* spp. root would have all four constituents available including the important polysaccharides and glycoproteins, provided the starting material is of good quality.

### **Adulterants**

Adulteration of *Echinacea* products has a long and twisted history. Some of the original studies done in Germany on *Echinacea* were actually done on *Parthenium integrifolium* (prairie dock or Missouri snakeroot) which is a common adulterant and has significantly different chemistry.<sup>17,18</sup> On discovering this, the Germans made attempts to grow their own specimens and ended up with *E. purpurea* which they thought were *E. angustifolia*. To make matters worse, in other attempts to study *E. angustifolia* the Germans eventually discovered that it was misrepresented as *E. pallida*.<sup>12</sup> Unfortunately this adulteration was not limited to the 1980s. A research group found that an *E. angustifolia* shipped to them was actually an *E. pallida* in the late 1990s.<sup>19</sup> This confusion on species is almost certainly still occurring for researchers and companies that do not have proper identification procedures in place. Many of the early chemical and pharmacological studies of *Echinacea* were not vouchered and cannot be attributed unequivocally to a given species.

### **Pharmacokinetics**

#### *Absorption of Hydroxycinnamic acids*

In order to fully discuss the absorption of hydroxycinnamates in *Echinacea*, it is necessary to first examine the research from other plant species. Hydroxycinnamic acids are one of the major classes of phenolic acids. Members of this group are ubiquitous in food stuffs, herbal medicines and beverages such as coffee. This group includes cinnamic acid, cichoric acid, coumaric acid, ferulic acid, rosmarinic acid, cynarin, caftaric acid, caffeic acid, and chlorogenic acid.

Gut absorption of caffeic acid is well characterized in both humans and animal models.<sup>20-25</sup> However, the absorption of chlorogenic acid is more controversial. Some groups have failed to detect chlorogenic acid in the plasma of humans or rats after ingestion as either a pure compound, or coffee, a rich source of chlorogenic acid.<sup>26</sup> However, metabolites of chlorogenic acid, caffeic acid derivatives and its O-methylated metabolites (e.g. ferulic acid) are commonly found in plasma and urine after ingestion of chlorogenic acid in humans and rats.<sup>22,27-29</sup> This research shows that chlorogenic acid is absorbed and quickly metabolized, particularly into its methylated derivative, ferulic acid, by catechol-O-methyltransferase which is present in the intestines.<sup>30</sup> Others have shown metabolites of chlorogenic acid, such as ferulic acid, isoferulic acid, vanillic acid, dihydroferulic acid, hippuric acid and 3-hydroxyhippuric acid, are detected in human urine samples after ingestion of multiple cups of coffee.<sup>31</sup>

However, caffeic acid is better absorbed than chlorogenic acid. In human studies with volunteers who had undergone colonic resection, chlorogenic acid absorption was a third of caffeic acid absorption.<sup>32</sup> Other studies concur, Lafay *et al.* utilizing a murine model, reported that while 19.5% of caffeic acid is absorbed in small intestines only, 8.0% of chlorogenic acid is absorbed in small intestines.<sup>33</sup> The time frame for maximum concentration in human plasma for caffeic acid has been reported to be one hour.<sup>27</sup>

In the case of *Echinacea*, we are particularly interested in caftaric acid, cynarin, caffeic acid, chlorogenic acid, cinnamic acid and echinacoside. The occurrence of these compounds differs depending on the particular *Echinacea* species. While one *in vitro* study done on an *Echinacea* product showed absorption of only about 3% of ingested cichoric acid and 1% of caftaric acid over 90 minutes, there was a substantial absorption of cinnamic acid (83%) over the same time frame.<sup>34</sup> However, this research was on a specific *Echinacea* product and the results differ significantly from other research that examined hydroxycinnamate pharmacokinetics. For example, in a murine model, caftaric acid was detected in plasma at 10 minute (293 ng/mL) and 20 minute (334 ng/mL) time points. By 20 minutes a derivative of caftaric acid, fertaric acid, was detected in plasma as well.<sup>35</sup> Caftaric acid was detected in kidney, and in some animals, in the brain. In general, hydroxycinnamates are eliminated rapidly from the circulatory system with  $t_{1/2}$  (half-life) values ranging from 0.3 to 1.9 h.<sup>36</sup>

#### *Alkylamide absorption*

The alkylamides have also been studied for absorptive capacity. Thus far, it has been reported that the higher the unsaturation of the alkylamide, the higher the absorbability. For example, the 2,4-diene alkylamides have been reported to cross Caco cells more readily than 2-ene alkylamides (see table 1).<sup>34</sup> Incidentally, *E. purpurea* has a higher concentration of 2,4-dienes (table 1, compounds 3, 4 & 5) than *E. angustifolia*, which has a higher concentration of 2-ene alkylamides (table 1, compound 9).<sup>37</sup>

The concentrations of alkylamides reported in serum have been between 10.88 - 336 ng/mL.<sup>38-43</sup> The  $t_{1/2}$  of the predominant alkylamide dodeca-2,4,8,10-tetraenoic acid isobutylamide in a murine model has been reported to be 71.9 minutes,<sup>43</sup> while in another study a  $t_{1/2}$  of 0.4 -1.03 hr. was observed for the same compound.<sup>42</sup> Of particular interest, two independent studies have reported that there is no difference between alkylamide absorption between liquid extracts (tinctures) and tablets except for a delay in  $t_{max}$  which would be expected due to the necessary digestion of the tablet.<sup>42,44</sup> One group reported alkylamides being detectable in serum for up to 12 hours.  $T_{1/2}$  values range from 1.8 – 5.0 depending on the molecular structure of the alkylamide.<sup>39</sup>

Murine models investigating alkylamide absorption have shown that the alkylamides cross the blood-brain barrier with an elimination half-life of 253 minutes with a mean residence of 323 minutes.<sup>39</sup> Others have reported a rapid passage across the blood-brain barrier.<sup>43</sup> This may be correlated with *Echinacea's* recently reported anxiolytic activity.<sup>45-47</sup>

#### **Traditional Use:**

The native Americans utilized *Echinacea* for a number of uses including as an anesthetic, analgesic, for coughs and sore throats and as an antidote for poisons such as snake venom.<sup>48</sup> The physicians of the early 20<sup>th</sup> century learned many of these uses from the native Americans and utilized *Echinacea* for many indications, including sepsis, as well as less severe infections.<sup>49</sup> At this point in time, *Echinacea* spp. have been documented in therapeutic use for more than a century by physicians for a variety of infections (Couch and Giltner, 1920). Even though 80% of the *Echinacea* products sold to consumers are

made from *purpurea*,<sup>1</sup> all three species are often used interchangeably for the treatment of cold, flu, respiratory infection, and inflammation.<sup>50</sup> However, this crossover between species and plant parts for the same indications should be examined more closely for further refinement in indications. With further evolution of the understanding of the clinical effects of various extractions and constituents of *Echinacea*, an enhanced understanding of species and products will develop.

### **Modern Use**

*Echinacea* is one of the most frequently used medicinal plants in clinical settings. There are more than 800 *Echinacea* products on the market.<sup>51</sup> For example, of the most prescribed drugs in Germany, *Echinacea* preparations have been in the top 200 for many years.<sup>52</sup> Despite the hesitancy to use *Echinacea* products clinically in the U.S., German physicians have written over 3 million prescriptions annually for *Echinacea* products for the treatment of upper respiratory tract infections for well over a decade.<sup>53,54</sup>

Medical doctors, naturopathic physicians and professional clinical herbalists in the U.S. have utilized *E. purpurea* as an acute remedy for upper respiratory tract infections. In addition, for clinicians comfortable with *Echinacea* as an immune enhancer, it is used as an addition to antimicrobials to improve the therapeutic outcome. For example, *Echinacea* added to an antifungal regime of topical econazole nitrate reduced fungal reoccurrence rates from 60.5% to 16.7%.<sup>55</sup> Those clinicians with more in depth understanding of *Echinacea* may also use it to accelerate wound healing both topically and internally.

### **Indications**

Indications given are for *E. purpurea* root.<sup>56</sup>

1. The common cold, flu, and upper respiratory tract infections.
2. General immune system function.
3. Vaginal candidiasis in combination with an antifungal.
4. Non-healing wounds (topical or oral formulation).
5. Prophylaxis of common cold, flu, and upper respiratory tract infections. (weak evidence)

### **Where does the research point?**

The bottom line: The most consistent results identified by the majority of the studies previous to the year 2000 indicate that *Echinacea* has nonspecific immunostimulating properties through the triggering of the innate immune system.<sup>57-67</sup> However, more recent work indicates that *Echinacea* is a true immunomodulator and in some cases may be useful for conditions exhibiting an autoimmune response.<sup>68-75</sup>

Research suggest that *Echinacea* species have immunological effects, as well as anti-viral, antibacterial, antifungal, insecticidal and anti-inflammatory properties.<sup>76</sup> Although there is ongoing controversy in the literature as to whether the immunomodulating properties of *Echinacea* are attributable to the alkylamides, caffeic acid derivatives or the polysaccharides/glycoproteins, the *in vitro* and *in vivo*

investigations previously performed demonstrate that there are multiple compounds that are active. Full spectrum extracts are, based on research, clinical experience and this author's opinion, the wisest choice of therapeutic application for *Echinacea* products.

A great deal of excitement has been generated due to the recent elucidation of the alkylamides activity on cannabinoid 2 receptors (CB2R; see section below entitled Cannabinoid activity).<sup>77,78</sup> Some in the natural products industry now think that the basis of *Echinacea's* activity has finally been established. This may be short-sighted as CB2R activation comes up short as an explanation as to the various observations clinicians and researchers have made. If the alkylamide activation of CB2R was the primary basis of activity for *Echinacea* it would suggest that *Echinacea* is essentially a complex antiinflammatory. Both research and clinical experience strongly suggest otherwise. Most of the *Echinacea* preparations that have shown an effect in clinical trials are not impressively high in alkylamides and contain the caffeic acid derivatives and often the polysaccharide/glycoproteins as well.<sup>79-82</sup> Extracts that contain a wide spectrum of constituents currently appear to be the most reasonable direction for clinical use since it is not clear what compounds are the most important.<sup>10,11</sup>

However, the CB2 activity strongly does suggest that *Echinacea* may also be used for a broader array of immune dysregulation than its current indications. For, example CB2R activation is therapeutic in autoimmune diseases.<sup>83-85</sup> While the chemically complex *Echinaceas* is not as simple as a one constituent pharmaceutical might be, this may challenge the Commission E's contraindication of autoimmune diseases for *Echinacea*.<sup>86</sup>

Interesting new directions in Echinacea research investigate a much wider application than immune issues. Recent research suggests the possibility that *Echinacea* may be useful in type II diabetes and metabolic syndrome, although this still needs further work.<sup>68,69</sup> The CB2 activity alone would potentially be useful in these conditions.<sup>87,88</sup> However alkylamides have been shown in two independent models to activate PPAR- $\gamma$ , the site of action of the thiazolidines commonly used to treat insulin resistance, diabetes, elevated triglycerides and CRP levels.<sup>68,69</sup> Investigations on gene response show that *E. purpurea* root extract upregulates PPAR- $\gamma$  expression in cells infected by human rhinovirus and the polysaccharides of *E. purpurea* extracts upregulate PPAR expression in non-infected cells.<sup>89</sup> Provided that the PPAR activity can be shown *in vivo*, Echinacea may have an intriguing new indication on the horizon.

## ***In vitro* and *Ex vivo* activity**

### **Immunomodulation**

Immunomodulators are defined as agents that modulate the dynamic regulation of immunologically relevant informational molecules such as cytokines, hormones, neurotransmitters and other proteins and peptides.<sup>74,75</sup> Physiological effects of *Echinacea* include immunomodulatory activities, such as stimulation of phagocytosis<sup>58-61</sup> and induction/inhibition of cytokines from various leukocytes depending on the research model utilized.<sup>62-67</sup> In addition, investigators report antioxidant activity.<sup>70,71,90-93</sup> Immunostimulating activity of extracts from *Echinacea* appear to be well established as well.<sup>58,64,94-97</sup>

Studies have reported that *Echinacea* extracts have the ability to activate human phagocytic function both *in vitro* and *in vivo*.<sup>58,64,96,98,99</sup>

Other researchers have noted up-regulation of immune function in *ex vivo* models<sup>93</sup> including in human immunodeficiency disorders.<sup>95</sup> Conversely, down regulation of TNF- $\alpha$  and IL-8 have been demonstrated by *E. purpurea* extracts in *ex vivo* models of healthy individuals.<sup>100</sup> While this appears contradictory, keep in mind that the 'physiological context' appears to be crucial as to *Echinacea*'s direction of the pharmacological effect. One of these studies examined individuals with immunodeficiency disorders,<sup>95</sup> the other examined healthy individuals.<sup>100</sup> Intriguingly, *E. purpurea* extracts appear to function differently in a healthy individual's system than in an ill individual's system.

In human cells lines that are infected by a pathogen, a normal response is the upregulation of proinflammatory cytokines to counteract the infection. Recall that during upper respiratory tract infections (URIs) upregulation of inflammatory cytokines is responsible for the majority of clinical symptoms.<sup>101</sup> A number of studies demonstrate that *E. purpurea* extracts will counteract this proinflammatory response due to infection from virus or bacteria.<sup>70-72</sup> This has been suggested to be the main effect of *Echinacea* by many in the natural products industry whom have suggested that *Echinacea* is a simple CB2R agonist. Furthermore, interviews with experts on *Echinacea* from the natural products industry are quick to point out that *Echinacea* is not an antibiotic, rather the majority of its action is due to immunomodulatory activity. While there is quite a significant body of research on the immunomodulatory activity of *Echinacea*, there is also a body of research on specific antimicrobial activity.

*E. purpurea* has been shown to have "potent virucidal activity against viruses with membranes" including specific rhinoviruses, influenza virus, respiratory syncytial virus, adenovirus types 3 and 11, and herpes simplex virus type 1.<sup>70</sup> In addition, antibacterial activity has been found against pathogenic bacteria such as *Streptococcus pyogenes*, *Hemophilus influenza*, *Legionella pneumophila*, *Propionibacterium acne* and *Clostridium difficile*.<sup>71,72</sup> In recent studies that received very little attention, investigators showed that the virus known as H5N1 HPAIV was inhibited from replication and entry into cells by an *E. purpurea* extract. Moreover, while oseltamivir (Tamiflu®) induced resistance after multiple passages, *E. purpurea* extract did not induce resistance. These researchers also found that oseltamivir resistant virus were sensitive to *E. purpurea*.<sup>102</sup> Other *in vitro* experiments show that *E. purpurea* extracts have the potential for use in alleviating the symptoms and pathology associated with infections with H1N1 influenza A virus by attenuating the production of TNF- $\alpha$ , G-CSF, CCL2/MCP-1, CCL3/MIP-1alpha and CCL5/RANTES from infected cells.<sup>13</sup> In monocytes exposed to aerial or root extracts of *E. purpurea*, upregulation of IL-1 $\alpha$ , TNF- $\alpha$ , ICAM, IL-8, and IL-10 was observed consistent with an activated antiviral physiological response. In these studies, the aerial vs. root extracts did not differ significantly in their effects.<sup>103</sup> Recall that both aerial parts of the plant and the root contain the hydroxycinnamates and the alkylamides, although in different concentrations.

Cyclooxygenase (COX) and COX-2 inhibition, as well as minor lipoxygenase inhibition have also been noted for *Echinacea* extracts and specific alkylamides.<sup>13,104-107</sup> This would potentially have an additive, or possibly synergic effect in the anti-inflammatory activity that the CB2R activation has demonstrated.











While the inhibition of proinflammatory cytokines and chemokines in infection will make a significant difference in symptoms of upper respiratory tract infections, the anti-inflammatory activity and the direct antibacterial/antiviral activity will also be important. Add to these actions the inhibition of mucin secretion by goblet cells in the respiratory tract when infected by rhinovirus<sup>72</sup> and the direct upregulation of phagocytosis<sup>58,64,96,98,99</sup> and it is obvious that *E. purpurea* has multiple activities that should not be attributed to one class of constituents or one pharmacological target.

### **Cannabinoid activity**

The alkylamides (examples shown in table 1, compounds 3, 4, 5, 9 & 10) found in *Echinacea* species and other medicinal plants, have been of pharmacological interest since humans first noted the tingling and numbing effect from chewing plants rich in these compounds.<sup>108</sup> This anesthetizing tingling of these compounds is associated with activation of tactile and thermal trigeminal neurons.<sup>109</sup> This property was utilized by native Americans<sup>48</sup> and eventually by physicians in the early 20<sup>th</sup> century for a variety of purposes including toothache and infections.<sup>49</sup> Alkylamides were later recognized as insecticidal by a number of researchers,<sup>108,110-112</sup> but eventually interest in these compounds waned. Recently, however, these fatty acid derivatives have become a subject of renewed interest due to their recent identification as cannabinoid ligands. The endogenous cannabinoid ligands are specific fatty acid metabolites, known as eicosanoids.<sup>87</sup> It should be explicitly stated that the alkylamides do not interface with the cannabinoid 1 receptor, which is responsible for the psychotropic effects of the cannabinoids from *Cannabis* spp.<sup>77,78,113,114</sup>

The CB2R is located on T & B lymphocytes, natural killer cells, macrophages, neutrophils, and mast cells and provides immunomodulatory responses.<sup>115</sup> The CB2R has been found to play a significant role in immune dynamics including the resolution of inflammation, cancer, atherosclerosis, osteoporosis and chronic pain.<sup>113</sup> This is a particularly attractive site for cannabinoid agonists selective for CB2R because of a paucity of psychomimetic activity. Nonetheless, in the face of remarkable volumes of preclinical data, only one CB2 drug molecule (cannabinor) has made it to phase II clinical trials.<sup>116</sup> Data from marijuana smokers provide leading clues as to the effects of CB<sub>2</sub> ligands on immune function. Lung alveolar macrophages removed from marijuana smokers have diminished capacity for the generation of TNF, gmCSF and IL-6 (inflammatory cytokines).<sup>117</sup> Moreover, marijuana smokers that are matched with tobacco smokers for the frequency of smoking, have significantly lower rates of lung cancer than tobacco smokers or non-smokers.<sup>118</sup> Further data suggest that CB<sub>2</sub> ligands can inhibit the production of TNF and other cytokines by several different pathways, some independent of cannabinoid receptors.<sup>115</sup> Conversely, cannabinoids have also been shown to increase the production of cytokines (including TNF, IL-1, IL-6, and IL-10) if administered with appropriate immune stimulation (bacteria or antigens)<sup>115</sup> or, in some cases, without immune stimulation.<sup>119</sup> These data strongly suggest true immunomodulation and not simple immunosuppression by *Echinacea*. Again, it should be stated that *Echinacea* has no

**Table 1. Ligands of CB2 and PPAR $\gamma$**

CB2 ligands	PPAR $\gamma$ ligands
 <p>1. Anandamide MW 347.3</p>	 <p>6. 15-deoxy-<math>\Delta^{12,14}</math>-prostaglandin J<sub>2</sub> MW 316.4 (fibroblasts activity 7 <math>\mu</math>M)</p>
 <p>2. 2-arachidonylglycerol MW 378.3 (PPAR<math>\gamma</math>)</p>	 <p>7. 13-hydroxyoctadecadienoic acid MW 296.4</p>
 <p>3. Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide MW 247.3 from <i>Echinacea</i> spp.</p>	 <p>8. 13-oxooctadecadienoic acid MW 294.4</p>
 <p>4. Dodeca-2E,4E-ene-dienoic acid isobutylamide MW 251.3 from <i>Echinacea</i> spp.</p>	 <p>9. Undeca-2E-ene-8,10-diynoic acid isobutylamide MW 231.3 from <i>Echinacea</i> spp.</p>
 <p>5. Dodeca-2E,4E,8Z-trienoic acid isobutylamide MW 249.3 from <i>Echinacea</i> spp.</p>	 <p>10. Hexadeca-2E,9Z,12Z,14E-tetraenoic acid isobutylamide MW 303.3 from <i>Echinacea</i> spp.</p>

- a. When information was available concentrations found to be active are stated.  
 b. Compounds 3 & 4 are also PPAR $\gamma$  activators. from <sup>76</sup>with Ki of 57 nM and 60 nM. <sup>78</sup>



psychotropic effects as the alkylamides of *Echinacea* do not bind to the CB1 receptor found in the central nervous system.

Induction of tumor necrosis factor (TNF) mRNA by alkylamides is greatest (12 fold) with alkylamides known as the tetraene isomers at a concentration of 5  $\mu$ M.<sup>114</sup> Another alkylamide common to both *E. purpurea* and *E. angustifolia* is dodeca-2E,4E-dienoic acid isobutylamide, which also upregulated TNF mRNA 9 fold. Dodeca-2E,4E,8Z-trienoic acid isobutylamide, also common to *purpurea* and *angustifolia* up regulates TNF mRNA five-fold. The effect of these alkylamides on TNF is blocked by the CB2R antagonist WR144528.<sup>114</sup> In another study on CB2R binding, investigators demonstrated that the isobutylamides dodeca-2E,4E,8Z,10Z-tetraenoic acid (table 1, compound 3) and dodeca-2E,4E-dienoic acid (compound 4) inhibited the binding of a CB<sub>2</sub> ligand.

Other studies confirm similar affinities for these alkylamides.<sup>78</sup> Notably, these affinities are within range of serum concentrations previously observed (10.88 - 336 ng/mL).<sup>38-43</sup> Other observations in these studies include the activation of MEK 1/2 as well as JNK1/2 and NF- $\kappa$ B.<sup>114</sup>

As previously mentioned, extracts with a wide array of constituents, not focused primarily on alkylamides appear to be important. For example, while TNF- $\alpha$  induction has been induced by the alkylamides, one of the caffeic acid derivatives, cichoric acid (also known as, chichoric acid), as well as extracts of *E. purpurea* and *E. angustifolia* roots have demonstrated counteraction of increases in TNF- $\alpha$  levels.<sup>120</sup> Again these data suggest that the effects of *Echinacea* may be dependent on the immunological “tone” of the system as well as the type of extract.

#### **Human Research *in vivo/ex vivo*:**

While a number of clinical trials have shown a beneficial effect for *Echinacea* spp. on colds and flus,<sup>82,121-125</sup> a number of trials have failed to show a reduction of the symptoms of colds and flus.<sup>126-128</sup> For example, Turner *et al*<sup>127</sup> demonstrated no effect of *E. angustifolia* on the reduction of symptoms or duration of an experimentally induced cold.

Further research with an *E. purpurea* extract that was dosed with a loading dose (5 mL for 8 doses) for the first day and subsequently 5 mL three times daily for 6 days, in volunteers with URIs demonstrated a reduction in cold symptoms compared to placebo from days 2-7 of treatment (constituent doses 0.25/2.5/25.5 mg/mL alkylamides, cichoric acid, polysaccharides, respectively). In *ex vivo* analysis of these subjects' blood, the number of circulating total white blood cells, monocytes, neutrophils and NK cells was significantly increased by the 7<sup>th</sup> day of treatment. In the later stages of the cold, the *Echinacea* treatment normalized the increase in neutrophilic superoxide production by day 8 while the placebo group continued to show increases in superoxide production up to day 8.<sup>82</sup>

The most recent clinical trial to date studied *E. purpurea* mixed with *E. angustifolia* and weighted heavily with alkylamide concentrations in 1422 subjects, showed a non-statistical effect on shortening colds and flus. In addition, the researchers reported an increase in neutrophils and IL-8. However, due to high inter-individual variability this was not statistically significant.<sup>126</sup>

Despite the negative outcomes, there are enough positive data in the human trials to offset the negative results. As a result, the meta-analyses that have been performed suggest that *Echinacea* products are effective.<sup>124,129-131</sup> A Cochrane review reports some *Echinacea* preparations may be better than placebo and that the majority of the *Echinacea* studies demonstrate positive results.<sup>129</sup> A meta-analysis by Schoop *et al.*,<sup>130</sup> reports that standardized extracts of *Echinacea* were effective in the prevention of symptoms of the common cold as compared with placebo. Islam and Carter<sup>131</sup> conclude that there is a beneficial effect from *Echinacea*, but also suggest that differences in products and doses make evaluation challenging.<sup>129</sup> Linde *et al.*<sup>124</sup> suggest that there is evidence, although inconsistent, that *Echinacea* is effective in treating URIs. A meta-analysis of studies with children (< 18 y/o) found that *Echinacea* reduces the incidence of URIs by 40%.<sup>132</sup> Finally, the most recent meta-analysis finds that the evidence supports *Echinacea's* benefit in decreasing the incidence and duration of the common cold in adults.<sup>133</sup>

Recent data on 995 patients with chronic recurrent respiratory disease shows that treatment with an *E. purpurea* extract reduces the incidence of illness by 2.3 times and saves 1.4 days with each illness. These researchers calculated the average daily cost per patient and reported that there is an economic benefit to the use of *Echinacea*.<sup>81</sup>

In a study of URI prevention, subjects were dosed with 2.5 mL three times daily of *E. purpurea* extract or placebo, for 7 days. After the initial 7 days of dosing the subjects were inoculated with rhinovirus and dosed with another 7 days of *E. purpurea* extract or placebo. URIs developed in 58% of the *Echinacea* group as compared to 82% of placebo recipients.<sup>134</sup> A recent trial which failed to show a positive outcome for treating URIs in children (2 – 11 y/o) with *E. purpurea* did find that there was a prophylactic effect reducing the incidence of a second acute respiratory tract infection over a four month period.<sup>135</sup> In a study of athletes, an *E. purpurea* tablet was rated as “good” or above by 75% of subjects and investigators and prevented colds in 71% of the subjects.<sup>136</sup> *Echinacea* products to date have never resulted in a false positive for banned substances used by athletes. A meta-analysis of the prevention studies suggest that there is a 55% reduction in the occurrence in URIs when using *Echinacea* as compared to placebo.<sup>137</sup>

In another human *ex vivo* study researchers gave 1500 mg three times daily of capsule of *E. purpurea* aerial parts and roots and *E. angustifolia* root to human subjects for 2 days + one additional morning. After the dosing period a downregulation of a number of inflammatory genes was observed in most subjects; IL-1 $\beta$  (4 of 6 subjects); TNF- $\alpha$  (5 of 6 subjects); IL-8 (3 of 6 subjects); COX-2 (4 of 6 subjects); and ICAM-1 (4 of 6 subjects). These results achieved statistical significance on day 5, despite dosing having ceased 2 days earlier. Conversely, the relative expression of IFN- $\alpha$ 2, an endogenous antiviral cytokine found to decrease symptoms and duration of colds, increased steadily in all subjects reaching statistical significance by day 12.<sup>103</sup> Another study found that after 7 days of dosing with *E. purpurea* extract, immune function, measured by CD69 expression on CD4 and CD8 cells, was upregulated.<sup>138</sup>

Other research has shown that a lozenge of *E. purpurea* root in a range of doses (0.07 – 0.9 mg alkylamides) downregulates the production of IL-12p70, IL-8, IL-6, IL-10 and TNF within 24 hours of the

dose.<sup>139</sup> These researchers also showed that the alkylamides in the *E. purpurea* product were absorbed in 10 minutes, suggesting that absorption is taking place through the oral mucosa.

Brinker<sup>79</sup> has done an excellent analysis of *Echinacea* clinical trials and pointed out that of the studies that have shown an effect on URIs, the products used were all liquid extracts. Further analysis by Brinker has suggested that of the studies that failed, none used liquid extracts.<sup>79</sup> Thus, Brinker speculates that liquid extracts may be a more efficacious dosing strategy, especially considering the small doses that have been used in the clinical trials. An important factor when treating URIs may be oral mucosal exposure to the extract.<sup>139</sup> However, both small and large infrequent doses of whole fresh plant extract tablets have produced benefit.<sup>79</sup> In studies of the liquid juice (above ground parts of the plant) using frequent and early but small doses or larger infrequent doses of the juice<sup>125</sup> positive effects have been achieved, but not with regular moderate doses of the dried juice.

A recent review of the *Echinacea* clinical trials showed that less than 9% of studies that had a “high-quality” rating incorporated phytochemical testing as an investigational criteria.<sup>79</sup> As Cooper<sup>140</sup> points out, clarity and consistency on identity and dosing are essential for validating and comparing outcomes when carrying out research. Researchers who study specific product formulations administered in appropriate doses will vastly improve the quality of available data.

### **Clinical Observations**

While *Echinacea* preparations, properly dosed, are generally associated with the treatment of URIs, they can be potentially effective for the treatment of many different types of infections. Keep in mind that the Eclectic physicians of the late 19<sup>th</sup> century and early 20<sup>th</sup> century used *Echinacea* spp. for sepsis. In the case of infections, proper dosing is crucial (see Dosage section).<sup>141</sup> In addition, topical *Echinacea* can be useful for non-healing and spreading wounds. For instance, in combination with turmeric (*Curcuma longa*), both internally and topically, *E. purpurea* root has been useful for the particularly difficult-to-heal bites of brown recluse spiders (*Loxosceles reclusa*). A clinical observation of a brown recluse bite that occurred two years before herbal treatment makes an interesting case study. The bite had progressed into severe dermonecrotic lesions migrating up the left arm and down the right arm. The lesions were resolved over about 16 weeks’ time with topical and internal use of *E. purpurea radix* and *Curcuma longa rhizoma*. This is likely due to *Echinacea*’s stimulation of fibroblast activity, its hyaluronidase inhibition and its wound healing properties.<sup>142-144</sup> Native Americans also used *Echinacea* for rattlesnake bites. It is quite likely that the anti-hyaluronidase effect is the basis of this anti-venom activity, since viper venom contains hyaluronidase allowing it to break down connective tissue.<sup>145</sup>

One of the most intriguing uses of *Echinacea* in 1:1 combination with dandelion root have been the reports of attenuating IgE mediated allergic responses to food and other substances.<sup>146</sup> However, until conclusive evidence is available, life threatening allergic responses should be treated with proper medical care.

## What's New (LECTURE WILL FOCUS ON THIS SECTION OF THE MONOGRAPH)

A study in humans athletes demonstrated a significant increase in erythropoietin and IL-3.<sup>147</sup> Echinacea has also shown interesting anxiety reducing activity in humans.<sup>148</sup> In Russia, *E. purpurea* tops are mixed with animal feeds to improve the natural resistance of cattle to diseases, and improve milk production and quality.<sup>149</sup> A study in horses showed that Echinacea is effective in strengthening immune response and acts as a hematinic agent, increasing hemoglobin levels, the number of red blood cells, and improves exercise physiology parameters and performance.<sup>150</sup> A recent experiment in aquaculture showed that Echinacea improved weight gain, resistance against infection, resistance to cold stress during the winter season, and survival in fish.<sup>151</sup> *Echinacea* is proving to be so useful that numerous attempts have been underway in some non-traditional *Echinacea* growing countries, in Africa, Asia, Latin America, and the Middle East to introduce cultivation, processing, and marketing.<sup>149</sup>

- Ergogenic effect – performance enhancement in athletes & animals, climbers, skiers
  - Increases in hemoglobin, IL-3 & erythropoietin<sup>147,150</sup>
  - Protective – in athletes prevention of colds<sup>136</sup>
- Anxiolytic activity – in human subjects with mild, but clinically relevant anxiety<sup>148</sup>
- Enhancement of insulin sensitivity – theoretical, PPAR-γ activity, (think MetS & T2DM)<sup>68,69</sup>
- Brown recluse bites – case study, observed remarkable tissue healing effect
- IgE response – combined with *Taraxacum* multiple case studies showing significant resolution of symptoms<sup>146</sup>
- Growth Enhancement – livestock and fish<sup>149,151</sup>
- Galactagogue – improves milk production & quality in cattle<sup>149</sup>
- Autoimmune diseases –THEORITICAL,<sup>68,69,77,78,113,114</sup> and case studies, proceed with CAUTION
- Life extension – theoretical, research demonstrates extension of life in health & cancer models<sup>152-154</sup>

## Dosage

The suggested dose varies widely on various *Echinacea* products. Moreover, clinician's opinions on what dose is effective for the treatment of URIs vary extensively. But one thing appears to be obvious to most clinicians: The dosages suggested on most *Echinacea* products are subclinical and ineffective for most acute infections. Based on the above discussion of the pharmacokinetics of hydroxycinnamates and alkylamides which show half-lives of a few hours, as well as clinical experience, the efficacious dose of *E. purpurea* root extract for treating URIs is 1 teaspoon (of a liquid extract) as a loading dose (or 1500 mg capsule), followed by a half a teaspoon (or 500-750 mg capsule) every one-two hours for the first day (sleep should not be interrupted). While this may sound like a high dose there is support for this dosing regimen.<sup>82,155</sup> The following two days one teaspoon (1500 mg capsule) should be used three times a day to make sure the virus doesn't regain a foothold. For preventing an impending URI this dosing regimen must be started *at the first signs of illness*. This dosing protocol is based on the most common extract available 1:2 fresh root extracts. Clarks rule should be used for dosing children age 2-17 based on the above dosing. Clark's rule is as follows: (Child's weight in pounds / 150)(Adult dose) = Child's dose.

If consumer use is to support general immune function a lower dose is used. In this case half a teaspoon is used once daily of the liquid extract (or 750 – 1000 mg capsule).

### **Safety & Herb Drug Interactions**

The search for and appraisal of information relating to the metabolism of phytochemicals and the phytochemical influence on drug metabolism has thus far been a challenge for researchers and educators, and readily accessible information among the scientific and medical community is lacking. Metabolic studies on phytochemicals have only recently been published in the scientific literature. Unfortunately, it appears that in regard to phytochemical influence on the metabolism of pharmaceuticals, much of the literature does not evaluate the quality of evidence from which conclusions are drawn.<sup>8</sup>

Of particular concern for healthcare providers, Freeman and Spelman<sup>8</sup> report that drug-herb interactions related to *Echinacea* products were cited in some 49 articles, only 16% (8) of these 49 papers contained primary data relevant to interactions between *Echinacea* products and pharmaceuticals. Two studies were clinical trials<sup>156,157</sup> and the remaining were *in vitro* assays, three of which did not contain complete information about the concentration of extract used;<sup>158-160</sup> only half of the studies verified the authenticity of the *Echinacea*.<sup>156,160-162</sup> Essentially, what this suggests is that 84% of the scientific papers on *Echinacea* HDI information are reviews. In other words, the same information from a particularly study gets cited repeatedly, whether the evidence is of good quality or poor quality. This creates the illusion of generous amounts of evidence when in reality, there is not.

The most clinically relevant study done to date on the potential of *Echinacea* spp. to interact with pharmaceuticals was a study done on HIV patients (n = 15) who were receiving antiretroviral therapy including darunavir-ritonavir (600/100 mg twice daily) for at least 4 weeks.<sup>163</sup> *E. purpurea* root capsules (500 mg every 6 hr) for 14 days were used by patients. Darunavir-ritonavir plasma concentrations were determined before, during and after the *E. purpurea* dosing. Although patients did show a decrease in darunavir concentrations, this did not affect the overall darunavir or ritonavir pharmacokinetics. Coadministration of *E. purpurea* with darunavir-ritonavir was safe and well tolerated.

The available data on the metabolic influence of *Echinacea* spp. and the alkylamides mainly focuses on the predominant alkylamides known to be responsible for drug interactions such as the CYP1, CYP2 and CYP3 families. Three different reviews conclude that *Echinacea* supplements pose minimal risks for interacting with most conventional medications.<sup>8,164,165</sup>

Regarding concentrations of alkylamides used in *in vitro* research; recall that the highest serum concentration documented for alkylamides is 336 ng/mL and this was 10 fold higher than the majority of pharmacokinetic studies investigating these concentrations.<sup>38-43</sup> This should provide information for realistic analysis of future drug-herb interaction literature.

### *Cytochrome P450 Isoenzymes*

Studies show *E. purpurea* herb and root may minimally inhibit CYP1A2. Patients taking drugs with a narrow therapeutic index metabolized by CYP1A2 (e.g. theophylline and clozapine) should avoid taking

them with *E. purpurea*. However, studies conclude that no clinically significant interactions were expected between *E. purpurea* and substrates of CYP2D6, CYP2C19 and CYP2E1. There is no reliable research on *E. purpurea*'s interaction with CYP2C9.

#### CYP3A4

There are a number of investigations done with real world dosing with humans on *E. purpurea* root extracts influence on CYP3A4. Human investigations by Gorski *et al.*, (2004), found no changes in the metabolism of midazolam, a 3A4 substrate, after participants ingested 1600 mg of *E. purpurea* root daily for 8 days. While the authors observed an 85% increase in intestinal availability of midazolam, a 15% reduction of hepatic availability ( $p < 0.003$ ) was also noted. The authors postulated that the induction of hepatic 3A4 counteracted inhibition of intestinal 3A4, leading to little to no effect in midazolam metabolism overall.<sup>156</sup> Using *E. purpurea* whole plant extract (aerial and root combined) in a human trial Gurley *et al.* (2004) found no statistically significant differences in 3A4 phenotypic ratios. CYP 450 phenotypic ratios have been shown to provide a practical method for predicting CYP mediated drug interactions.<sup>157</sup> Finally, in another human trial with healthy volunteers (n = 13) given lopinavir (400 mg-ritonavir 100 mg twice/day) with meals for 29.5 days, found that *E. purpurea* (500 mg 3 times a day for 28 days) induced CYP3A activity but did not alter lopinavir concentrations.<sup>166</sup> The authors concluded that *E. purpurea* is unlikely to alter the pharmacokinetics of ritonavir-boosted protease inhibitors.

#### *Organic anion-transporting polypeptide (OATP-B)*

Fuchikami *et al.*,<sup>167</sup> found inhibition of OATP-B by the aerial parts of *E. purpurea in vitro*. The clinical significance of this finding is unclear, as few drugs are metabolized via this pathway and the findings have not been demonstrated *in vivo*.

#### *P-glycoprotein*

Romiti *et al.*,<sup>168</sup> report that the hexane root extracts of all three *Echinacea* species inhibited P-glycoprotein, with *E. pallida*, a little used species, having an effect at 3  $\mu\text{g}/\text{mL}$ . The *E. angustifolia* and *E. purpurea* extracts were inhibitory at 30  $\mu\text{g}/\text{mL}$ .<sup>168</sup> Considering the concentrations of the extracts used in this study, these data appear to have no relevance to real world use of *Echinacea* spp., especially since the percentage of *E. pallida* extracts in the market place is less than 5%.

Although drug-herb interactions are generally thought to be negative, there are potentially positive drug-herb interactions due to the potential of immune enhancement by *Echinacea*. For example, *Echinacea* may protect white blood cell counts in chemotherapy induced myelosuppression from myelosuppressive antineoplastic chemotherapies. In therapies exploiting TNF- $\alpha$  antagonists and other immunosuppressive drugs, *Echinacea* may theoretically be used to protect against opportunistic infection by enhancing cellular immunity during temporary drug withdrawals.<sup>169</sup>

*Echinacea* is considered to be one of the safest herbal medicines, with few reported adverse effects.<sup>170-</sup><sup>172</sup> Given that *Echinacea* generally ranks in the top five in herbal sales in the U.S. from year to year, this is particularly notable. Barrett<sup>171</sup> notes that less than 100 serious adverse events have been reported for over 10 million courses of treatment, leaving the risk estimate of less than 1 in 100,000. *Echinacea*

products consisting of roots and aerial parts do not appear to be a risk to consumers provided that the preparations are authenticated.<sup>8</sup>

### **Adverse Events & Toxicology**

Short-term use of *Echinacea* is associated with a relatively good safety profile, with a slight risk of transient, reversible, adverse events. In clinical trials the most common complaint was gastrointestinal side effects. Adverse events are rarely reported with *Echinacea*, though in rare cases *Echinacea* has been associated with severe allergic reactions. The severe allergic responses are predominantly with the use of intravenous or intramuscular injection. Mild reported allergies, though rare, suggest that those with tendencies towards atopic dermatitis or asthma should use caution.<sup>173</sup> People are more likely to experience allergic reactions to *Echinacea* if they are allergic to related plants in the daisy family, which includes ragweed, chrysanthemums, marigolds, and daisies. In ethanol extracts, since the proteins are denatured, allergic response to the ethanol extracts should not occur. It should be noted that a good quality liquid extract (made with ethanol) of *Echinacea*, due to the alkylamide content, will induce a sensation of numbness and tingling on the tongue, mouth and throat. It is possible if the user is not expecting this sensation, it could be mistaken as an allergic reaction.

There appears to be no *in vivo* toxic level, i.e. overdose level, as defined by several assays and criteria of *Echinacea* spp.<sup>58,174,175</sup> Research shows the toxic dose of *E. purpurea* is extremely high; chronic administration of hundreds of times the therapeutic dose has shown no toxicity.<sup>174</sup> Furthermore, inducing toxic effects on cell cultures by *E. purpurea* extracts are possible with only with very high concentrations of *Echinacea* extracts that would not be possible to attain in even high dose use by humans.<sup>176</sup>

### **Tips on Products**

While *Echinacea* products are ubiquitous in the market place, it can be challenging to distinguish between these products in regard to quality of product, proper part of plant used and, importantly, ease of use for the consumer. Most American generated products are made with root and/or flower and seed. These parts provide the highest availability of alkylamides and will have reasonable levels of caffeic acid derivatives. Polysaccharides will be present if these plant parts are put into capsule, but if extracted with ethanol, polysaccharides are present only in substantial concentrations if the ethanol concentration is below 40%. Conversely, most European based products (primarily German) are juiced above ground parts of the plant. These products will be rich in caffeic acid derivatives and polysaccharides, but low in alkylamides (notice the lack of numbing and tingling from one of these products – a sure sign of very low alkylamide content).

Clinicians in the U.S. prefer products richer in alkylamides since these are CB2R agonists. However, alkylamides are not the only active constituent in *Echinacea*. Since a primary active constituent in *Echinacea* has yet to be identified, a full spectrum phytochemical extract is a prudent choice.

For consumer use, the easiest approach is probably in liquid extract form. The taste of *Echinacea* can be (mostly) hidden in juice or teas. However, the capsule is easier if consumers are sensitive to the taste. For both capsules and liquid extracts, proper dosing is important if attempting to shorten the discomfort of an URI.

## References

1. Li TSC. Echinacea: Cultivation and medicinal value. *HortTechnology*. 1998;8:122-129.
2. Kim HO, Durance TD, Scaman CH, Kitts DD. Retention of alkaloids in dried Echinacea purpurea. *J Agric Food Chem*. Sep 2000;48(9):4187-4192.
3. Bruneton J. *Pharmacognosy Phytochemistry Medicinal Plants*. Paris: Lavoisier; 1995.
4. Bauer R. [Echinacea drugs--effects and active ingredients]. *Z Arztl Fortbild*. Apr 1996;90(2):111-115.
5. Chen Y, Fu T, Tao T, et al. Macrophage activating effects of new alkaloids from the roots of Echinacea species. *J Nat Prod*. May 2005;68(5):773-776.
6. Hudson J, Vimalanathan S, Kang L, Amiguet VT, Livesey J, Arnason JT. Characterization of antiviral activities in Echinacea root preparations. *Pharm Biol*. Dec 2005;43(9):790-796.
7. Williamson E. Interactions between herbal and conventional medicines: the role of cytochrome P450 enzymes and P-glycoprotein. *PharmacologyOnline*. 2006;2:200-205.
8. Freeman C, Spelman K. A critical evaluation of drug interactions with *Echinacea* spp. *Molecular nutrition & food research*. Jul 10 2008;52:789-798.
9. Zheng Y, Dixon M, Saxena PK. Growing environment and nutrient availability affect the content of some phenolic compounds in *Echinacea purpurea* and *Echinacea angustifolia*. *Planta Med*. Dec 2006;72(15):1407-1414.
10. Zhai Z, Solco A, Wu L, et al. Echinacea increases arginase activity and has anti-inflammatory properties in RAW 264.7 macrophage cells, indicative of alternative macrophage activation. *J Ethnopharmacol*. 2009;122(1):76-85.
11. Dalby-Brown L, Barsett H, Landbo AKR, Meyer AS, Molgaard P. Synergistic Antioxidative Effects of Alkaloids, Caffeic Acid Derivatives, and Polysaccharide Fractions from *Echinacea purpurea* on in Vitro Oxidation of Human Low-Density Lipoproteins. *J. Agric. Food Chem*. November 30, 2005 2005;53(24):9413-9423.
12. Bauer R, Khan IA, Wagner H. TLC And HPLC Analysis Of *Echinacea pallida* And *E. angustifolia* Roots. *Planta Med*. Oct 1988;54(5):426-430.
13. Cech NB, Kandhi V, Davis JM, Hamilton A, Eads D, Laster SM. Echinacea and its alkaloids: Effects on the influenza A-induced secretion of cytokines, chemokines, and PGE(2) from RAW 246.7 macrophage-like cells. *Int Immunopharmacol*. Jul 29 2010.
14. Pugh ND, Tamta H, Balachandran P, et al. The majority of in vitro macrophage activation exhibited by extracts of some immune enhancing botanicals is due to bacterial lipoproteins and lipopolysaccharides. *Int Immunopharmacol*. Jul 2008;8(7):1023-1032.
15. Tamta H, Pugh ND, Balachandran P, Moraes R, Sumiyanto J, Pasco DS. Variability in in vitro macrophage activation by commercially diverse bulk echinacea plant material is predominantly due to bacterial lipoproteins and lipopolysaccharides. *J Agric Food Chem*. Nov 26 2008;56(22):10552-10556.
16. Brinker F. Variations in Effective Botanical Products: The Case for Diversity of Forms for Herbal Preparations as Supported by Scientific Studies. *HG, J Am Bot Coun*. 1999;46:36-50.
17. Bauer RFX, Khan IA, Lotter H. Structure and stereochemistry of new sesquiterpene esters from *Echinacea purpurea* (L.) Moench. *Helvetica Chimica Acta*. 1985;68(8):2355-2358.
18. Bauer R, Khan I, Wagner H. Echinacea preparations. *ECHINACEA-DROGEN*. 1986;126(20):1065-1070.
19. Rogers KL, Grice ID, Mitchell CJ, Griffiths LR. High performance liquid chromatography determined alkaloid levels in Australian-grown Echinacea spp. *Aust J Exper Agric*. 1998;38(4):403-408.



20. Teuchy H, Van Sumere CF. The metabolism of (1- 14 C) phenylalanine, (3- 14 C) cinnamic acid and (2- 14 C) ferulic acid in the rat. *Arch Int Physiol Biochim.* Aug 1971;79(3):589-618.
21. Camarasa J, Escubedo E, Adzet T. Pharmacokinetics of caffeic acid in rats by a high-performance liquid chromatography method. *J Pharm Biomed Anal.* 1988;6(5):503-510.
22. Azuma K, Ippoushi K, Nakayama M, Ito H, Higashio H, Terao J. Absorption of chlorogenic acid and caffeic acid in rats after oral administration. *Journal of agricultural and food chemistry.* Nov 2000;48(11):5496-5500.
23. Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans. *J Nutr.* Jan 2001;131(1):66-71.
24. Simonetti P, Gardana C, Pietta P. Caffeic acid as biomarker of red wine intake. *Methods Enzymol.* 2001;335:122-130.
25. Scalbert A, Morand C, Manach C, Remesy C. Absorption and metabolism of polyphenols in the gut and impact on health. *Biomed Pharmacother.* Aug 2002;56(6):276-282.
26. Choudhury R, Srai SK, Debnam E, Rice-Evans CA. Urinary excretion of hydroxycinnamates and flavonoids after oral and intravenous administration. *Free radical biology & medicine.* Aug 1999;27(3-4):278-286.
27. Nardini M, Cirillo E, Natella F, Scaccini C. Absorption of phenolic acids in humans after coffee consumption. *Journal of agricultural and food chemistry.* Sep 25 2002;50(20):5735-5741.
28. Rechner AR, Pannala AS, Rice-Evans CA. Caffeic acid derivatives in artichoke extract are metabolised to phenolic acids in vivo. *Free radical research.* Aug 2001;35(2):195-202.
29. Wittemer SM, Ploch M, Windeck T, et al. Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans. *Phytomedicine.* Jan 2005;12(1-2):28-38.
30. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. *Pharmacol Rev.* Dec 1999;51(4):593-628.
31. Rechner AR, Spencer JP, Kuhnle G, Hahn U, Rice-Evans CA. Novel biomarkers of the metabolism of caffeic acid derivatives in vivo. *Free radical biology & medicine.* Jun 1 2001;30(11):1213-1222.
32. Olthof MR, Hollman PC, Buijsman MN, van Amelsvoort JM, Katan MB. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. *J Nutr.* Jun 2003;133(6):1806-1814.
33. Lafay S, Morand C, Manach C, Besson C, Scalbert A. Absorption and metabolism of caffeic acid and chlorogenic acid in the small intestine of rats. *Br J Nutr.* Jul 2006;96(1):39-46.
34. Matthias A, Blanchfield JT, Penman KG, et al. Permeability studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell monolayer model. *J Clin Pharm Ther.* Feb 2004;29(1):7-13.
35. Vanzo A, Cecotti R, Vrhovsek U, Torres AM, Mattivi F, Passamonti S. The fate of trans-caftaric acid administered into the rat stomach. *Journal of agricultural and food chemistry.* Feb 21 2007;55(4):1604-1611.
36. Stalmach A, Mullen W, Barron D, et al. Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption. *Drug Metab Dispos.* Aug 2009;37(8):1749-1758.
37. Spelman K, Wetschler MH, Cech NB. Comparison of alkylamide yield in ethanolic extracts prepared from fresh versus dry Echinacea purpurea utilizing HPLC-ESI-MS. *J Pharm Biomed Anal.* 2009;49(5):1141-1149.
38. Dietz B, Heilmann J, Bauer R. Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture. *Planta Med.* Dec 2001;67(9):863-864.

39. Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. *Life Sci.* Sep 2 2005;77(16):2018-2029.
40. Matthias A, Addison RS, Agnew LL, Bone KM, Watson K, Lehmann RP. Comparison of alkamide pharmacokinetics between equivalent liquid and tablet echinacea preparations. *Phytomed.* 2007;14(9):587-590.
41. Woelkart K, Koidl C, Grisold A, et al. Bioavailability and pharmacokinetics of alkamides from the roots of *Echinacea angustifolia* in humans. *J Clin Pharmacol.* Jun 2005;45(6):683-689.
42. Woelkart K, Dittrich P, Beubler E, et al. Pharmacokinetics of the main alkamides after administration of three different *Echinacea purpurea* preparations in humans. *Planta Med.* May 2008;74(6):651-656.
43. Woelkart K, Frye RF, Derendorf H, Bauer R, Butterweck V. Pharmacokinetics and Tissue Distribution of Dodeca-2E,4E,8E,10E/Z-tetraenoic Acid Isobutylamides after Oral Administration in Rats. *Planta Med.* Apr 27 2009.
44. Matthias A, Addison RS, Agnew LL, Bone KM, Watson K, Lehmann RP. Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations. *Phytotherapy.* Sep 2007;14(9):587-590.
45. Hajos N, Holderith N, Nemeth B, et al. The Effects of an Echinacea Preparation on Synaptic Transmission and the Firing Properties of CA1 Pyramidal Cells in the Hippocampus. *Phytother Res.* Jun 30 2011.
46. Haller J, Hohmann J, Freund TF. The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. *Phytother Res.* Nov 2010;24(11):1605-1613.
47. Hohmann J, Redei D, Forgo P, et al. Alkamides and a neolignan from *Echinacea purpurea* roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. *Phytochemistry.* Oct 2011;72(14-15):1848-1853.
48. Moerman DE. *Native American ethnobotany.* Portland, Or.: Timber Press; 1998.
49. Ellingwood F. History, Character and Physiological Action. *Ellingwood's Therapeutist.* 1917;11(Feb):4-6.
50. Bauer R, Foster S. Analysis of alkamides and caffeic acid derivatives from *Echinacea simulata* and *E. paradoxa* roots. *Planta Med.* Oct 1991;57(5):447-449.
51. Sun L, Rezaei KA, Temelli F, Ooraikul B. Supercritical fluid extraction of alkylamides from *Echinacea angustifolia*. *J Agric Food Chem.* Jul 3 2002;50(14):3947-3953.
52. Der Marderosian AH. The Need for Cooperation Between Modern and Traditional Medicine. *HerbalGram J Am Bot Coun.* 1991;24:30.
53. Tyler VE. Phytomedicines in Western Europe: their potential impact on herbal medicine in the United States. *HG J Am Bot Counc.* 1994;30:24-31.
54. Keller K. Legal Requirements For The Use Of Phytopharmaceutical Drugs In The Federal-Republic-Of-Germany. *J Ethnopharmacol.* Apr 1991;32(1-3):225-229.
55. Coeugnet E, Kuhnast R. [Recurrent candidiasis: Adjuvant immunotherapy with different formulations of Echinacea]. *Therapiwoche* 1986;36:3352-3358.
56. Blumenthal M, Goldberg A, Brinckmann J. *Herbal Medicine: Expanded Commission E Monographs.* Integrative Medicine Communications; 2000.
57. Zhai Z, Liu Y, Wu L, et al. Enhancement of innate and adaptive immune functions by multiple *Echinacea* species. *J. Med. Food.* Sep 2007;10(3):423-434.
58. Melchart D, Linde K, Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. *J Altern Complement Med.* Summer 1995;1(2):145-160.

59. Bauer VR, Jurcic K, Puhlmann J, Wagner H. [Immunologic in vivo and in vitro studies on Echinacea extracts]. *Arzneimittelforschung*. Feb 1988;38(2):276-281.
60. Jurkštienė V, Kondrotas AJ, Kėvelaitis E. Compensatory reactions of immune system and action of Purple Coneflower (Echinacea purpurea (L.) Moench) preparations. *Medicina (Kaunas)*. 2004;40(7):657-662.
61. Wildfeuer A, Mayerhofer D. Influence of phytopreparations on the cellular function of body defense. *Arzneim Forsch*. 1994;44(3):361-366.
62. Cundell DR, Matrone MA, Ratajczak P, Pierce JD. The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat. *Int Immunopharmacol*. Jul 2003;3(7):1041-1048.
63. Hwang SA, Dasgupta A, Actor JK. Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts. *Clin Chim Acta*. May 2004;343(1-2):161-166.
64. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. *Int J Immunopharmacol*. Jul 1997;19(7):371-379.
65. Stevenson LM, Matthias A, Banbury L, et al. Modulation of macrophage immune responses by Echinacea. *Molecules*. Oct 2005;10(10):1279-1285.
66. Senchina DS, Strauch JH, Hoffmann GB, et al. Phytochemical and Immunomodulatory Properties of an Echinacea laevigata (Asteraceae) Tincture. *J Altern Complement Med*. Apr 2011;17(4):375-377.
67. Fusco D, Liu X, Salvatore M, et al. Echinacea purpurea aerial extract alters course of influenza infection in mice. *Vaccine*. Apr 8.
68. Spelman K, Iiams-Hauser K, Cech NB, Taylor EW, Smirnov N, Wenner CA. Role for PPAR $\gamma$  in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8,10-dienoic acid isobutylamide. *Int Immunopharmacol*. 2009;9:1260-1264.
69. Christensen KB, Petersen RK, Petersen S, Kristiansen K, Christensen LP. Activation of PPAR $\gamma$  by Metabolites from the Flowers of Purple Coneflower (Echinacea purpurea). *J Nat Prod*. Apr 17 2009;72(5):933-937.
70. Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. *Antiviral research*. Apr 29 2009.
71. Sharma SM, Anderson M, Schoop SR, Hudson JB. Bactericidal and anti-inflammatory properties of a standardized Echinacea extract (Echinaforce((R))): Dual actions against respiratory bacteria. *Phytomedicine*. Dec 24 2009.
72. Sharma M, Schoop R, Hudson J. The efficacy of Echinacea in a 3-D tissue model of human airway epithelium. *Phytother Res*. Dec 8 2009.
73. Spelman K, Aldag R, Hamman A, et al. Traditional herbal remedies that influence cell adhesion molecule activity. *Phytother Res*. Apr 2011;25(4):473-483.
74. Spelman K, Burns JJ, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of Cytokine Expression by Traditional Medicines: A Review of Herbal Immunomodulators. *Alt Med Rev*. Jun 2006;11(2):128-150.
75. Burns JJ, Zhao L, Taylor EW, Spelman K. The influence of traditional herbal formulas on cytokine activity. *Toxicology*. Oct 7 2010;278(1):140-159.
76. Spelman K. *The extraction, stability, metabolism and bioactivity of the alkylamides in Echinacea spp*. Exeter, U.K.: School of Biosciences, University of Exeter; 2009.
77. Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R. The Endocannabinoid System as a Target for Alkamides from Echinacea angustifolia Roots. *Planta Med*. Aug 2005;71(8):701-705.

78. Raduner S, Majewska A, Chen J-Z, et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: Cannabinoid Type 2 Receptor-Dependent and -Independent Immunomodulatory Effects. *J Biol Chem*. May 19, 2006 2006;281(20):14192-14206.
79. Brinker F. Echinacea for upper respiratory viral infections: how differences in preparations matter. *Alt Med Alert*. 2008;11(4):41-45.
80. Schoop R, Buechi S, Suter A. Open, multicenter study to evaluate the tolerability and efficacy of Echinaforce Forte tablets in athletes. *Adv Ther*. Sep-Oct 2006;23(5):823-833.
81. Heinen-Kammerer T, Holtmannspotter C, Schnabel S, Motzkat K, Kiencke P, Rychlik R. [Effectiveness of echinacin in therapy of chronic recurrent respiratory disease]. *Gesundheitswesen*. Apr 2005;67(4):296-301.
82. Goel V, Lovlin R, Chang C, et al. A proprietary extract from the echinacea plant (*Echinacea purpurea*) enhances systemic immune response during a common cold. *Phytother Res*. Sep 21 2005;19(8):689-694.
83. Correa F, Docagne F, Mestre L, et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. *Biochemical pharmacology*. Jan 1 2009;77(1):86-100.
84. Sugiura T, Kondo S, Kishimoto S, et al. Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-cells. *J. Biol. Chem.* . January 7, 2000 2000;275(1):605-612.
85. Loria F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. *The European journal of neuroscience*. Aug 2008;28(4):633-641.
86. Blumenthal M, Busse WR, Bundesinstitut für Arzneimittel und Medizinprodukte (Germany). *The complete German Commission E monographs, Therapeutic guide to herbal medicines*. Austin, Texas: American Botanical Council; Integrative Medicine Communications; 1998.
87. Mackie K. Cannabinoid receptors as therapeutic targets. *Annu Rev Pharmacol Toxicol* 2006;46(1):101.
88. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? *Drugs*. 2008;68(15):2131-2162.
89. Altamirano-Dimas M, Hudson J, Cochrane D, Nelson C, Arnason J. Modulation of immune response gene expression by echinacea extracts: results of a gene array analysis. *Can J Physiol Pharmacol*. 2007;85(11):1091-1098.
90. Bauer R. Chemistry, analysis and immunological investigations of Echinacea phytopharmaceuticals. In: Wagner H, ed. *Immunomodulatory Agents from Plants*. Basel: Birkhäuser Verlag; 1999:41-88.
91. Hashemi SM, Soudi S, Ghaemi A, Soleimanjahi H, Hassan ZM. Study the effect of echinacea purpurea extract on cellular delayed type hypersensitivity and splenocyte proliferation in BALB/c mice. *Yakhteh*. 2008;9(4):254-261.
92. Hudec J, Burdova M, Kobida L, et al. Antioxidant Capacity Changes and Phenolic Profile of *Echinacea purpurea*, Nettle (*Urtica dioica* L.), and Dandelion (*Taraxacum officinale*) after Application of Polyamine and Phenolic Biosynthesis Regulators. *J. Agric. Food Chem*. 2007;55(14):5689-5696.
93. Skopinska-Rozewska E, Sokolnicka I, Siwicki AK, et al. Dose-dependent in vivo effect of *Rhodiola* and *Echinacea* on the mitogen-induced lymphocyte proliferation in mice. *Polish journal of veterinary sciences*. 2011;14(2):265-272.
94. Sun LZ, Currier NL, Miller SC. The American coneflower: a prophylactic role involving nonspecific immunity. *J Altern Complement Med*. Oct 1999;5(5):437-446.

95. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. *Immunopharmacology*. Jan 1997;35(3):229-235.
96. Morazzoni P, Cristoni A, Di Pierro F, et al. In vitro and in vivo immune stimulating effects of a new standardized Echinacea angustifolia root extract (Polinacea). *Fitoterapia*. Jul 2005;76(5):401-411.
97. Maass N, Bauer J, Paulicks BR, Bohmer BM, Roth-Maier DA. Efficiency of Echinacea purpurea on performance and immune status in pigs. *J Anim Physiol Anim Nutr (Berl)*. Aug 2005;89(7-8):244-252.
98. Percival SS. Use of echinacea in medicine. *Biochem Pharmacol*. Jul 15 2000;60(2):155-158.
99. Roesler J, Steinmuller C, Kiderlen A, Emmendorffer A, Wagner H, Lohmann-Matthes ML. Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to mice mediates protection against systemic infections with Listeria monocytogenes and Candida albicans. *Int J Immunopharmacol*. 1991;13(1):27-37.
100. Woelkart K, Marth E, Suter A, et al. Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system. *Int J Clin Pharm Ther*. Sep 2006;44(9):401-408.
101. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: clinical background. *J Leukoc Biol*. Jan 2004;75(1):5-17.
102. Pleschka S, Stein M, Schoop R, Hudson JB. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). *Virology journal*. Nov 13 2009;6(1):197.
103. Randolph RK, Gellenbeck K, Stonebrook K, et al. Regulation of human immune gene expression as influenced by a commercial blended Echinacea product: Preliminary studies. *Exp Biol Med*. OCT 2003;228(9):1051-1056.
104. Lalone CA, Huang N, Rizshsky L, et al. Enrichment of Echinacea angustifolia with Bauer alkylamide 11 and Bauer ketone 23 increased anti-inflammatory potential through interference with cox-2 enzyme activity. *J Agric Food Chem*. Aug 11 2010;58(15):8573-8584.
105. Clifford LJ, Nair MG, Rana J, Dewitt DL. Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench. *Phytomed*. Apr 2002;9(3):249-253.
106. Hou CC, Chen CH, Yang NS, et al. Comparative metabolomics approach coupled with cell- and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants. *J Nutr Biochem*. Dec 9 2009.
107. LaLone CA, Rizshsky L, Hammer KD, et al. Endogenous levels of Echinacea alkylamides and ketones are important contributors to the inhibition of prostaglandin E2 and nitric oxide production in cultured macrophages. *J Agric Food Chem*. Oct 14 2009;57(19):8820-8830.
108. Greger H. Alkamides: structural relationships, distribution and biological activity. *Planta Med*. Oct 1984;50(5):366-375.
109. Bryant BP, Mezine I. Alkylamides that produce tingling paresthesia activate tactile and thermal trigeminal neurons. *Brain Res*. 1999;842(2):452.
110. Towers GHN, Champagne DE. Medicinal phytochemistry of the Compositae: The activities of selected acetylenes and their sulfur derivatives. In: Lam J, Breteler H, Arnason T, Hansen L, eds. *Chemistry and biology of naturally-occurring acetylenes and related compounds (NOARC)*. Vol v7. Amsterdam; New York: Elsevier; 1988:139-178.
111. Jacobson M. Structure of echinacin, the insecticidal component of American coneflower roots. *J. Org. Chem*. 1967;32(5):1646-1647.
112. Jacobson M. Herculic acid, a pungent insecticidal constituent of Southern Prickly Ash Bark. *J Am Chem Soc*. 1948;70:4234-4237.

113. Gertsch J, Raduner S, Altmann KH. New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. *J Recept Signal Transduct Res.* 2006;26(5-6):709-730.
114. Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. *Febs Lett.* NOV 19 2004;577(3):563-569.
115. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol.* May 2005;5(5):400-411.
116. Högenauer EK. Latest advances in the cannabinoids. *Expert Opinion on Therapeutic Patents.* 2007;17(12):1457-1476.
117. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. *Am J Respir Crit Care Med.* Nov 1997;156(5):1606-1613.
118. Chen AL, Chen TJ, Braverman ER, et al. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. *Journal of psychoactive drugs.* Sep 2008;40(3):263-272.
119. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. *J Biochem.* Apr 2004;135(4):517-524.
120. Matthias A, Banbury L, Stevenson LM, Bone KM, Leach DN, Lehmann RP. Alkylamides from echinacea modulate induced immune responses in macrophages. *Immunol Invest.* 2007;36(2):117-130.
121. Goel V, Lovlin R, Barton R, et al. Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. *J Clin Pharm Ther.* Feb 2004;29(1):75-83.
122. Brinkeborn RM, Shah DV, Degenring FH. Echinaforce (R) and other Echinacea fresh plant preparations in the treatment of the common cold - A randomized, placebo controlled, double-blind clinical trial. *Phytomed.* Mar 1999;6(1):1-6.
123. Braunig B, Dorn M, Knick E. *Echinacea purpurea radix*: Zur stärke der körpereigenen abwehr bei grippalen infekten. *Z Phytother.* 1992;13:7-13.
124. Linde K, Barrett B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev.* 2006(1):CD000530.
125. Schulten B, Bulitta M, Ballering-Bruhl B, Koster U, Schafer M. Efficacy of Echinacea purpurea in patients with a common cold. A placebo-controlled, randomised, double-blind clinical trial. *Arzneimittelforschung.* 2001;51(7):563-568.
126. Barrett B, Brown R, Rakel D, et al. Echinacea for treating the common cold: a randomized trial. *Ann Intern Med.* Dec 21 2010;153(12):769-777.
127. Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. *N Engl J Med.* Jul 28 2005;353(4):341-348.
128. Schwarz E, Metzler J, Diedrich JP, Freudenstein J, Bode C, Bode JC. Oral administration of freshly expressed juice of Echinacea purpurea herbs fail to stimulate the nonspecific immune response in healthy young men: Results of a double-blind, placebo-controlled crossover study. *J Immunotherapy.* Sep-Oct 2002;25(5):413-420.
129. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev.* 2000;2(CD000530).
130. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: A meta-analysis. *Clin Therap.* Feb 2006;28(2):174-183.

131. Islam J, Carter R. Use of Echinacea in upper respiratory tract infection. *South Med J*. Mar 2005;98(3):311-318.
132. Del-Rio-Navarro BE, Espinosa RF, Flenady V, Sienra-Monge JLL. Immunostimulants for preventing respiratory tract infection in children. *Cochrane Database Syst Rev*. 2006;4(CD004974):DOI:10.1002/14651858.CD14004974.pub14651852.
133. Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. *The Lancet infectious diseases*. Jul 2007;7(7):473-480.
134. Sperber S, Shah L, Gilbert R, Ritchey T, Monto A. Echinacea purpurea for Prevention of Experimental Rhinovirus Colds. *Clin Infect Dis*. 2004;38(10):1367-1371.
135. Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C. Echinacea purpurea for prevention of upper respiratory tract infections in children. *J Altern Complement Med*. Dec 2005;11(6):1021-1026.
136. Sharma M, Schoop R, Suter A, Hudson JB. The potential use of Echinacea in acne: control of Propionibacterium acnes growth and inflammation. *Phytother Res*. Apr 2011;25(4):517-521.
137. Schoop R, Klein P, Suter A, Johnston SL. Echinacea in the prevention of induced rhinovirus colds: a meta-analysis. *Clin Ther*. Feb 2006;28(2):174-183.
138. Brush J, Mendenhall E, Guggenheim A, et al. The effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humans. *Phytother Res*. Aug 2006;20(8):687-695.
139. Guiotto P, Woelkart K, Grabnar I, et al. Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with Echinacea purpurea extract. *Phytomedicine*. Jun 24 2008.
140. Cooper R. Contribution of pharmacognosy to clinical trials of botanicals and dietary supplements. *Altern Compl Med*. 2007;13(9):1045-1046.
141. Ellingwood F, Lloyd JU. Echinacea. Echinacea angustifolia. In: Ellingwood F, Lloyd JU, eds. *American materia medica, therapeutics and pharmacognosy*. Vol downloaded from <http://www.henriettesherbal.com/eclectic/ellingwood/echinacea.html>. Chicago, Evanston, Ill., 1919.
142. Rousseau B, Tateya I, Lim X, Munoz-del-Rio A, Bless DM. Investigation of anti-hyaluronidase treatment on vocal fold wound healing. *J Voice*. Sep 2006;20(3):443-451.
143. Zhai Z, Haney DM, Wu L, et al. Alcohol extract of Echinacea pallida reverses stress-delayed wound healing in mice. *Phytomedicine*. 2009;doi:10.1016/j.phymed.2009.02.010.
144. Facino RM, Carini M, Aldini G, et al. Direct characterization of caffeoyl esters with antihyaluronidase activity in crude extracts from Echinacea angustifolia roots by fast atom bombardment tandem mass spectrometry. *Farmaco*. Oct 1993;48(10):1447-1461.
145. Yingprasertchai S, Bunyasrisawat S, Ratanabanangkoon K. Hyaluronidase inhibitors (sodium cromoglycate and sodium auro-thiomalate) reduce the local tissue damage and prolong the survival time of mice injected with Naja kaouthia and Calloselasma rhodostoma venoms. *Toxicol : official journal of the International Society on Toxinology*. Nov 2003;42(6):635-646.
146. Spelman K. Echinacea purpurea radix and Taraxacum officinale radix ethanolic extracts ameliorate acute allergic reactions in two patients. *J Am Herb Guild*. 2008; 8(1):29-37.
147. Whitehead MT, Martin TD, Scheett TP, Webster MJ. The effect of 4 wk of oral echinacea supplementation on serum erythropoietin and indices of erythropoietic status. *International journal of sport nutrition and exercise metabolism*. Aug 2007;17(4):378-390.
148. Haller J, Freund TF, Pelczer KG, Furedi J, Krecsak L, Zambori J. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. *Phytother Res*. Jan 2013;27(1):54-61.

149. Letchamo W, Polydeonny LV, Gladisheva NO, Arnason TJ, Livesey J, Awang DVC. Factors affecting Echinacea quality. Paper presented at: Trends in new crops and new uses 2002; Alexandria, VA.
150. O'Neill W, McKee S, Clarke AF. Immunological and haematonic consequences of feeding a standardised Echinacea (*Echinacea angustifolia*) extract to healthy horses. *Equine Vet J*. May 2002;34(3):222-227.
151. Aly SM, Mohamed MF. Echinacea purpurea and Allium sativum as immunostimulants in fish culture using Nile tilapia (*Oreochromis niloticus*). *J Anim Physiol Anim Nutr (Berl)*. Apr 23 2010;94(5):e31-39.
152. Miller SC. Echinacea: a Miracle Herb against Aging and Cancer? Evidence In vivo in Mice. *Evid Based Complement Alternat Med*. September 1, 2005 2005;2(3):309-314.
153. Currier NL, Miller SC. Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated. *Exp Gerontol*. Aug 2000;35(5):627-639.
154. Currier NL, Miller SC. Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. *J Altern Complement Med*. Jun 2001;7(3):241-251.
155. Ritchie M, Gertsch J, Klein P, Schoop R. Effects of Echinaforce® treatment on ex vivo-stimulated blood cells. *Phytomedicine*. 2011;18(10):826-831.
156. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther*. Jan 2004;75(1):89-100.
157. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. *Clin Pharmacol Ther*. Nov 2004;76(5):428-440.
158. Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomed*. Jul 2000;7(4):273-282.
159. Foster B, Vandenhoeck S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. *Phytomedicine*. 2003;10(4):334-342.
160. Yale SH, Glurich I. Analysis of the Inhibitory Potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the Metabolic Activity of Cytochrome P450 3A4, 2D6, and 2C9. *J Altern Complement Med*. 2005;11(3):433-439.
161. Moulick K, Raner G. Effects of Echinacea on human metabolizing systems. 55th Southeast Regional Meeting of the American Chemical Society; 2003; Atlanta, GA.
162. Raner G, Cornelious S, Moulick K, et al. Effects of herbal products and their constituents on human cytochrome P450 2E1 activity. *Food Chem Toxicol*. 2007;45(12):2359-2365.
163. Moltó J, Valle M, Miranda C, et al. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. *Antimicrobial agents and chemotherapy*. 2011;55(1):326-330.
164. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic Herb-Drug Interactions (Part 2): Drug Interactions Involving Popular Botanical Dietary Supplements. *Planta medica*. 2012;78:1490–1514.
165. Toselli F, Matthias A, Gillam EM. Echinacea metabolism and drug interactions: The case for standardization of a complementary medicine. *Life Sci*. May 7 2009.
166. Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter Lopinavir-Ritonavir exposure in healthy subjects. *Pharmacotherapy*. 2010;30(8):797-805.



167. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. *Drug Metab Dispos.* Apr 2006;34(4):577-582.
168. Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B, Chieli E. P-Glycoprotein Inhibitory Activity of Lipophilic Constituents of *Echinacea pallida* Roots in a Human Proximal Tubular Cell Line. *Planta Med.* Feb 2008;74(3):264-266.
169. Stargrove MB, Treasure J, McKee DL. *Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies.* Mosby; 2007.
170. Hodges PJ, Kam PCA. The peri-operative implications of herbal medicines. *Anaesthesia.* Sep 2002;57(9):889-899.
171. Barrett B. Echinacea; a safety review *HG J Am Bot Counc.* 2003;57:36-39.
172. Gunning K. Echinacea in the treatment and prevention of upper respiratory tract infections. *West J Med.* Sep 1999;171(3):198-200.
173. Huntley AL, Thompson Coon J, Ernst E. The safety of herbal medicinal products derived from *Echinacea* species: a systematic review. *Drug Saf.* 2005;28(5):387-400.
174. Mengs U, Clare CB, Poiley JA. Toxicity of *Echinacea purpurea*. Acute, subacute and genotoxicity studies. *Arzneimittelforschung.* Oct 1991;41(10):1076-1081.
175. Lersch C, Zeuner M, Bauer A, et al. Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), thymostimulin, and *Echinacea purpurea* extracts (echinacin) in patients with far advanced colorectal cancers: preliminary results. *Cancer Invest.* 1992;10(5):343-348.
176. Coeugniet EG, Elek E. Immunomodulation with *Viscum album* and *Echinacea purpurea* extracts. *Onkologie.* 1987;10(3S):27-33.